

Approved for use through 10/31/2002. OMB 0651-0031  
 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995.  
 See The American Inventors Protection Act of 1999 (AIPA).

Application Number	09/619,560
Filing Date	July 19, 2000
First Named Inventor	Cheng, et al.
Group Art Unit	1764
Examiner Name	W.D. Griffin
Attorney Docket Number	2000B047

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 on the above-identified application.  
**NOTE:** 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Final Rule, 65 Fed. Reg. 50092 (Aug. 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office 47 (Apr. 11, 2000), which established RCE practice.

## 1. Submission required under 37 C.F.R. § 1.114

- a. ☐ Previously submitted
- i. ☐ Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on \_\_\_\_\_  
 (Any unentered amendment(s) referred to above will be entered.)
- ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on \_\_\_\_\_
- iii. ☐ Other \_\_\_\_\_
- b. ☒ Enclosed
- i. ☒ Amendment/Reply
- ii. ☒ Affidavit(s)/Declaration(s) - Declaration of Jane C. Cheng
- iii. ☐ Information Disclosure Statement (IDS)
- iv. ☐ Other \_\_\_\_\_

## 2. Miscellaneous

- a. ☐ Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period of \_\_\_\_\_ months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i) required)
- b. ☐ Other \_\_\_\_\_

## 3. Fees The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed.

- a. ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 05-1712
- i. ☒ RCE fee required under 37 C.F.R. § 1.17(e)
- ii. ☐ Extension of time fee (37 C.F.R. §§ 1.136 and 1.17)
- iii. ☐ Other \_\_\_\_\_
- b. ☐ Check in the amount of \$ \_\_\_\_\_ enclosed
- c. ☐ Payment by credit card (Form PTO-2038 enclosed)

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print/Type)	Darryl M. Tyus	Registration No. (Attorney/Agent)	40,853
Signature	<i>[Signature]</i>	Date	24 October 2002

## CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this communication is being facsimile transmitted to the United States Patent and Trademark Office (Fax No. 703/872-9311) on 10-24-02.

Name (Print/Type)	Laura Clark
Signature	<i>[Signature]</i>
Date	10-24-02

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Assistant Commissioner for Patents, Box RCE, Washington, DC 20231.

Handwritten notes and signatures in the top right corner, including "H810", "10/28/02", and a signature.

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

J. C. Cheng et al

Confirmation No. 2046

Serial No. 09/619,560

Filed: July 19, 2000

For: ALKYLAROMATICS PRODUCTION

Examiner: W.D. Griffin

Group Art Unit: 1764

AMENDMENT UNDER 37 CFR 1.116Assistant Commissioner for Patents  
Washington, D.C. 20231FAX RECEIVED  
OCT 25 2002  
GROUP 1700

In response to the Examiner's rejection mailed August 5, 2002, please  
amend the claims as follows and consider the ensuing remarks below.

IN THE CLAIMS:

Please amend claims 3 to 5 and 16 to 18 as follows:

3. (Amended) The process of claim 1, wherein the first crystalline molecular sieve  
is selected from MCM-22, MCM-36, MCM-49 and MCM-56.

4. (Amended) The process of claim 1, wherein the second crystalline molecular  
sieve comprises TEA-mordenite having an average crystal size of less than 0.5  
micron.

5. (Amended) The process of claim 1, wherein the transalkylation catalyst  
comprises about 15 to about 50% by weight of the first crystalline molecular  
sieve and about 15 to about 50% by weight of the second crystalline molecular  
sieve, based on the total weight of molecular sieve material in the catalyst.